CN Patent

CN120826242A — 抗cd20抗体药物偶联物在制备治疗套细胞淋巴瘤的药物中的用途

Assigned to Zhejiang Teruisi Pharmaceutical Inc · Expires 2025-10-21 · 1y expired

What this patent protects

一种抗CD20抗体药物偶联物在制备治疗套细胞淋巴瘤的药物中的用途，所述药物在治疗复发或难治套细胞淋巴瘤上具有良好的临床疗效，安全可控，满足了目前未被满足的临床需求。

USPTO Abstract

一种抗CD20抗体药物偶联物在制备治疗套细胞淋巴瘤的药物中的用途，所述药物在治疗复发或难治套细胞淋巴瘤上具有良好的临床疗效，安全可控，满足了目前未被满足的临床需求。

Drugs covered by this patent

Patent Metadata

Patent number
CN120826242A
Jurisdiction
CN
Classification
—
Expires
2025-10-21
Drug substance claim
No
Drug product claim
No
Assignee
Zhejiang Teruisi Pharmaceutical Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.